SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is being linked to anticipation of founder Patrick Soon-Shiongs Piper Sandler oncology symposium chat, where he is expected to discuss trial progress; traders are also watching for updates on bladder-cancer programs and international expansion. Some bullish posts speculate about a partnership or short squeeze, but those claims remain unverified.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is drawing attention around its Coinbase listing and Midnights network rollout, including Google Clouds validator involvement. Traders welcome the added access and infrastructure milestones, though reactions are mixed as some see room for a recovery while others point to weak follow-through and nearby resistance.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is drawing attention around volatile price action, with traders debating whether its apparent resilience versus Bitcoin can lead to a recovery or breakout. Some point to the planned CashVM/Layla upgrade as a potential catalyst, while skeptics highlight BCHs underperformance, weak perceived utility, and risk of further declines.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas non-binding plan to acquire its first U.S. data center and expand its AI infrastructure footprint is drawing attention. Some traders view the move as strategic growth, while many question how it will be financed and whether the company can execute, with those concerns accompanying the selloff.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile plans to become a wireless carrier have fueled concern that T-Mobile could face greater long-term competition, contributing to a sharp selloff in telecom stocks. Traders are divided between viewing SpaceX as a future threat and calling the reaction excessive because building a competitive terrestrial network would require substantial investment and time.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

RYCEY is drawing attention amid a persistent pullback, with traders debating whether the weakness reflects market and geopolitical pressure or a change in the companys outlook. Long-term bulls point to aerospace and defense demand, Rolls-Royces India engine plans and SMR prospects, while speculation about an unannounced hyperscaler deal remains a recurring source of anticipation and skepticism.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Exchange delisting concerns and JASMYs weak, volatile price action are driving debate, with some traders warning of further downside while others say specific exchange changes are being misrepresented or are limited in scope. Bulls also point to rising JasmyChain activity and ecosystem development as signs of emerging utility, though skeptics question whether that activity will translate into meaningful adoption or token demand.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Uncertainty over NASAs delayed CLPS 2.0 lunar-contract awards is the main focus, with traders watching for a decision and debating whether Intuitive Machines could benefit. Bulls view a contract as a potential catalyst, while bears point to repeated delays, a persistent downtrend, and weakness across space stocks.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs Buy upgrade, citing Palantirs sovereign-AI and customized-software growth opportunities, is fueling attention alongside a breakout to new highs. Bulls are celebrating the momentum and speculating about a short squeeze, while skeptics argue the valuation is stretched and warn of a pullback.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

IOVAs rally is drawing attention amid the companys higher revenue outlook and expectations for upcoming melanoma, sarcoma and lung-cancer updates. Traders also point to a reported decline in short interest as a possible source of buying pressure, while others warn that the sharp run-up could give way to volatility and debate whether the NSCLC update will arrive on schedule.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gland Pharma Secures USFDA Tentative Approval for Generic Lumify Eye Drops

Hyderabad: Gland Pharma Limited has announced that it … the United States. Gland Pharma , headquartered in Hyderabad, is a pharmaceutical company primarily focused … powders, infusions, oncology drugs , and ophthalmic solutions. Gland Pharma is also known …

Gland Pharma Names Dr Jitendra Gangwal Vice President, Research & Development

New Delhi: Gland Pharma has appointed Dr … institutions and leading Indian pharmaceutical companies. Over the course … . Prior to joining Gland Pharma , Dr. Gangwal was associated … . Reddy’s Laboratories, Glenmark Pharmaceuticals , Alkem Laboratories, and FDC …

Brief India: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains and more

In this briefing: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base 1. Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains Aditya Infotech Ltd (6596564Z IN) (AIL) raised around US$151m in its IPO in August 2025. The lockup on its pre-IPO investors is set to expire soon. AIL is a CCTV/video surveillance provider company offering a range of advanced video security and surveillance products, technologies and solutions for enterprise and consumer segments under its CP PLUS brand. In this note, we will talk about the lockup dynamics and possible placement. 2. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation.

Brief India: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD and more

In this briefing: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength 1. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD We initiate coverage on LG Electronics India (LG) with an ADD rating and a TP of INR 1,545 per share, valuing it at 38x Mar-28E AEPS We like LG for its market leadership in core product categories, strong brand equity, consistent technological innovations and product launches, healthy balance sheet, robust return ratios, and low working capital needs LG is a leading player in washing machines, refrigerators, panel televisions, and inverter ACs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense and more

In this briefing: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength Primer: Jammu & Kashmir Bank (JKBK IN) - Jan 2026 Exencial Industry Tidings 1. Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Domestic Market Share & Profitability Outlook: Domestic demand witnessed a sharp inflection in Q3FY26 following the government’s landmark GST reduction, which catalysed industry growth to ~20.5% YoY versus a decline of ~0.4% in H1FY26. MSIL outperformed the industry with domestic volume growth of ~22%, supported by strong traction across small cars and SUVs. Management highlighted a revival in the small car segment, which transitioned from a “red zone” of negative growth to healthy expansion, aided by improved affordability and a 7% rise in first-time buyers, particularly upgrades from two-wheelers.

Gland Pharma Shares Surge Over 9%, Q3 FY26 Profit Rises 28% To ₹261 Crore

Gland Pharma shares surged over 9 percent after Q3 FY26 profit rose 28 percent and revenue grew 23 percent. Strong product launches, higher R&D spending, and heavy trading volumes boosted investor sentiment.The strong stock movement came after the Hyderabad-based drug maker announced its financial results for the third quarter of FY26 after market hours on Wednesday.

Gland Pharma Gets USFDA Approval for Olopatadine Ophthalmic Solution

… Regulations, 2015, Gland Pharma stated that the USFDA approval … United States market. Gland Pharma , established in 1978 and … injectable and ophthalmic-focused pharmaceutical company with operations across … in India. Gland Pharma stated that the approval …

These two companies will sell shovels during India’s semaglutide gold rush

Shaily Engineering Plastics Ltd and Gland Pharma Ltd, involved in the making and filling of injectable pens for semaglutide, stand to win big as patients will need these devices irrespective of which brand of the drug they choose.

Brief India: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale and more

In this briefing: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Westlife Foodworld Ltd - Resilience Amid Demand Softness; Maintain BUY Auto Monthly Sales Volume - October 2025 NOCIL Ltd - Pricing Pressure Continues; Global Uncertainties Adding to the Woes 1. PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale PVR Inox is piloting a full-service "dine-in" cinema concept in Bengaluru, while management confirms a major strategic shift towards an asset-light (FOCO) model for new screen expansion. The dine-in is a defensive move to protect premium Spend Per Head (SPH) against OTT, while the asset-light pivot is move to fix the balance sheet and scale in Tier-2/3. The company is re-engineering its business to be less dependent on its own capital, but its profitability remains entirely dependent on the one thing it cannot control: the content pipeline . 2. Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,487 Cr in Q2FY26, marking a 5.8% YoY growth, in line with our estimates.

Pharma stocks crack, Nifty Pharma Index slips over 2% as Trump unveils 100% tariff: 3 key factors investors must watch

… and patented drugs entering … pharma space include the likes of Natco Pharma , Laurus Labs, Alembic Pharma , Sun Pharma … , Gland Pharma , Ajanta Pharma , and Glenmark Pharmaceuticals … of Indian pharmaceutical exports. …

Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. The company was founded by P. V. N. Raju in 1978 and is headquartered in Sangareddy, India.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLAND.NSE Gland Pharma Ltd.

Latest GLAND.NSE News